Indegene Quarterly Results for Trading Insights
In Mar 2026, Indegene (INDGN) reported revenue ₹1,014 Cr and net profit ₹80 Cr — revenue +29.8% YoY. For annual financials, live price and key ratios, visit INDGN stock price BSE.
INDGN Quarterly Results — Revenue, Profit & EPS Highlights
Indegene latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. Also explore Indegene share price performance to track price trends across different timeframes.
- Revenue of ₹1,014 Cr in Mar 2026 (+23.1% vs Sept 2025, +29.8% vs Mar 2025)
- Net Profit of ₹80 Cr in Mar 2026 (-21.6% vs Sept 2025, -32.2% vs Mar 2025)
- EBITDA of ₹154 Cr in Mar 2026 (-3.8% vs Sept 2025)
- Operating Margin of 14.0% in Mar 2026 (-3.0pp vs Sept 2025)
- Earnings Per Share of ₹3.32 in Mar 2026 (-22.1% vs Sept 2025)
Indegene Quarterly Results — Revenue, EBITDA, Net Profit & EPS
INDGN quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Mar 2026 | Sept 2025 | Mar 2025 | Jun 2025 | Dec 2025 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 1,014 | 824 | 781 | 783 | 962 | 23.1% | 29.8% |
| Net Profit (₹ Cr) | 80 | 102 | 118 | 116 | 103 | - | - |
| EBITDA (₹ Cr) | 154 | 160 | 173 | 177 | 179 | - | - |
| EPS (₹) | 3.32 | 4.26 | 4.91 | 4.86 | 4.29 | - | - |
| Operating Margin (%) | 14.0% | 17.0% | 20.0% | 20.0% | 17.0% | - | - |
INDGN Share Price Trend — 1-Year Movement Across Quarterly Results
Indegene 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. Compare with INDGN fair value estimate to assess whether the stock is under or overvalued.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
INDGN vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Indegene latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Mar 2026 |
₹442,581.33 Cr | 1844.3 | 15,018 | 2,710 | +1.0% | +11.8% | 18.0% | 163.2 |
|
Divis Laboratories
Mar 2026 |
₹179,363.85 Cr | 6797.5 | 2,986 | 751 | +4.4% | +11.8% | 25.2% | 240.1 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹153,579.77 Cr | 4537.8 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 394.2 |
|
Cipla
Mar 2026 |
₹114,559.46 Cr | 1418.2 | 6,612 | 543 | -14.3% | -4.0% | 8.2% | 206.4 |
|
Dr Reddys Laborator…
Mar 2026 |
₹110,089.41 Cr | 1319.0 | 7,996 | 221 | -12.5% | -11.5% | 2.8% | 497.7 |
All amounts in ₹ Crores